semaglutide oral cardiovascular indication news 2025 semaglutide oral cardiovascular indication 2025 news At ADA 2025, the SOUL trial revealed that oral semaglutide ( GLP-1 Agonists in Cardiovascular Diseases:

Furthermore, they offer individual and wholesale pricing, should researchers prefer to make bulk purchases

Review supplier claims on your own

Recently, Szopa et al

Individuals who received Wegovy lost an average of 12.4% of their initial body weight compared to individuals who received a placebo

Rather than viewing natural alternatives and prescription medications as strictly competing options, many providers now adopt a staged approach informed by genetics, biomarkers, and clinical response

If you have excess weight and are prone to gastric ulcers, this becomes an additional reason to seek professional help with weight-loss